Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


The in vivo role of androgen receptor SUMOylation as revealed by androgen insensitivity syndrome and prostate cancer mutations targeting the proline/glycine residues of synergy control motifs.

Mukherjee S, Cruz-Rodríguez O, Bolton E, Iñiguez-Lluhí JA.

J Biol Chem. 2012 Sep 7;287(37):31195-206. doi: 10.1074/jbc.M112.395210. Epub 2012 Jul 24.


Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity.

He B, Gampe RT Jr, Hnat AT, Faggart JL, Minges JT, French FS, Wilson EM.

J Biol Chem. 2006 Mar 10;281(10):6648-63. Epub 2005 Dec 19.


Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation.

Mukherjee S, Thomas M, Dadgar N, Lieberman AP, Iñiguez-Lluhí JA.

J Biol Chem. 2009 Aug 7;284(32):21296-306. doi: 10.1074/jbc.M109.011494. Epub 2009 Jun 4.


Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function.

Li W, Cavasotto CN, Cardozo T, Ha S, Dang T, Taneja SS, Logan SK, Garabedian MJ.

Mol Endocrinol. 2005 Sep;19(9):2273-82. Epub 2005 May 26.


Androgen receptor exon 1 mutation causes androgen insensitivity by creating phosphorylation site and inhibiting melanoma antigen-A11 activation of NH2- and carboxyl-terminal interaction-dependent transactivation.

Lagarde WH, Blackwelder AJ, Minges JT, Hnat AT, French FS, Wilson EM.

J Biol Chem. 2012 Mar 30;287(14):10905-15. doi: 10.1074/jbc.M111.336081. Epub 2012 Feb 13.


Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.

Elhaji YA, Stoica I, Dennis S, Purisima EO, Lumbroso R, Beitel LK, Trifiro MA.

Hum Mol Genet. 2006 Mar 15;15(6):921-31. Epub 2006 Jan 31. Erratum in: Hum Mol Genet. 2006 May 1;15(9):1561. Lumbroso, Rose [added]; Beitel, Lenore K [added].


Allosteric conversation in the androgen receptor ligand-binding domain surfaces.

Grosdidier S, Carbó LR, Buzón V, Brooke G, Nguyen P, Baxter JD, Bevan C, Webb P, Estébanez-Perpiñá E, Fernández-Recio J.

Mol Endocrinol. 2012 Jul;26(7):1078-90. doi: 10.1210/me.2011-1281. Epub 2012 May 31.


Molecular cell biology of androgen receptor signalling.

Bennett NC, Gardiner RA, Hooper JD, Johnson DW, Gobe GC.

Int J Biochem Cell Biol. 2010 Jun;42(6):813-27. doi: 10.1016/j.biocel.2009.11.013. Epub 2009 Nov 30. Review.


SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells.

Kaikkonen S, Jääskeläinen T, Karvonen U, Rytinki MM, Makkonen H, Gioeli D, Paschal BM, Palvimo JJ.

Mol Endocrinol. 2009 Mar;23(3):292-307. doi: 10.1210/me.2008-0219. Epub 2008 Dec 30.


Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function.

Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua SA, Jaffray E, Hay RT, Palvimo JJ, Jänne OA, Pestell RG.

Mol Cell Biol. 2002 May;22(10):3373-88.


SUMOylation modulates the transcriptional activity of androgen receptor in a target gene and pathway selective manner.

Sutinen P, Malinen M, Heikkinen S, Palvimo JJ.

Nucleic Acids Res. 2014 Jul;42(13):8310-9. doi: 10.1093/nar/gku543. Epub 2014 Jun 30.


Melanoma antigen-A11 (MAGE-A11) enhances transcriptional activity by linking androgen receptor dimers.

Minges JT, Su S, Grossman G, Blackwelder AJ, Pop EA, Mohler JL, Wilson EM.

J Biol Chem. 2013 Jan 18;288(3):1939-52. doi: 10.1074/jbc.M112.428409. Epub 2012 Nov 21.


Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus.

Rytinki M, Kaikkonen S, Sutinen P, Paakinaho V, Rahkama V, Palvimo JJ.

Mol Cell Biol. 2012 Oct;32(20):4195-205. Epub 2012 Aug 13.


SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells.

Zheng Z, Cai C, Omwancha J, Chen SY, Baslan T, Shemshedini L.

J Biol Chem. 2006 Feb 17;281(7):4002-12. Epub 2005 Dec 15.


Mutations in the amino-terminal domain of the human androgen receptor may be associated with partial androgen insensitivity and impaired transactivation in vitro.

Holterhus PM, Werner R, Struve D, Hauffa BP, Schroeder C, Hiort O.

Exp Clin Endocrinol Diabetes. 2005 Sep;113(8):457-63.


Molecular basis of androgen insensitivity.

Brinkmann AO.

Mol Cell Endocrinol. 2001 Jun 20;179(1-2):105-9. Review.


Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation.

Sutinen P, Rahkama V, Rytinki M, Palvimo JJ.

Mol Endocrinol. 2014 Oct;28(10):1719-28. doi: 10.1210/me.2014-1035. Epub 2014 Aug 15.


Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase.

Asim M, Hafeez BB, Siddiqui IA, Gerlach C, Patz M, Mukhtar H, Baniahmad A.

J Biol Chem. 2011 Oct 28;286(43):37108-17. doi: 10.1074/jbc.M111.292771. Epub 2011 Aug 19.


A G577R mutation in the human AR P box results in selective decreases in DNA binding and in partial androgen insensitivity syndrome.

Nguyen D, Steinberg SV, Rouault E, Chagnon S, Gottlieb B, Pinsky L, Trifiro M, Mader S.

Mol Endocrinol. 2001 Oct;15(10):1790-802.


Alternatively spliced androgen receptor variants.

Dehm SM, Tindall DJ.

Endocr Relat Cancer. 2011 Sep 20;18(5):R183-96. doi: 10.1530/ERC-11-0141. Print 2011 Oct. Review.

Supplemental Content

Support Center